Princeton, United States
Kardigan, founded in 2023, is making strides in the biotech space by targeting the global challenge of cardiovascular disease, the leading cause of death worldwide. Their mission, aptly captured in their slogan, "Cardiovascular disease is the leading cause of death in the world. We are developing novel medicines to change that," emphasizes their innovative approach.
Specializing in cardiovascular drug development, Kardigan aims to move beyond mere symptom management towards functional cures. The company adopts a personalized medicine approach by aligning disease drivers with treatment responders identified through clinical trials. This patient-driven strategy aims not just to alleviate symptoms but to modify the disease’s underlying pathophysiology.
Operating on both the East and West Coast, Kardigan boasts a team rich in cardiovascular, biotechnology, and operational expertise. While specific details about investments are not provided, their strategic focus and innovative platform position them as a promising candidate for future investor interest.
